Open Menu

Meetings & Education

Meetings & Education

Research & Data

Practice & Patients

Career Development

News & Initiatives

Get Involved

A phase 2 study to determine the clinical and pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage II to IV (M0) resectable cutaneous squamous cell carcinoma (Neo-SCC).

download

Background: Cutaneous squamous cell carcinoma (cuSCC) is the second most common skin cancer worldwide (Bray et al. 2018). While 90% of cases are cured surgically (Kauvar et al. 2015), approx. 5% spread regionally or distantly, with an OS rate < 20% at 10 years if regional lymph nodes (LN) are involved (Ogata et al. 2019). Immunotherapy trials have shown efficacy in advanced disease. Neoadjuvant therapy (NAT) is a powerful treatment platform to rapidly assess drug activity in resectable cancers. In melanoma, a major path response to immunotherapy (≤10% viable tumor) correlates with low risk of recurrence in resectable stage III disease (Menzies et al. 2021), and improved OS and EFS when anti-PD1 monotherapy or in combination with anti-CTLA-4 is given neoadjuvantly vs. monotherapy adjuvant (adj) treatment (Patel et al. 2023; Blank et al. 2024). In a study of NAT anti-PD1 monotherapy with cemiplimab, in pts with resectable stage III or IV (M0) cuSCC (N = 20), 55% of pts had a path complete response (pCR) (0% viable tumour) (Ferrarotto et al. 2021). In a larger NAT cemiplimab trial (N = 79) 51% pts achieved pCR (Gross et al. 2022). The De-Squamate cuSCC trial, evaluating NAT anti-PD1 monotherapy with pembrolizumab (N = 27), showed a 63% combined rate of pCR and clinical complete response (CCR) resulting in the de-escalation of surgery and post operative radiotherapy (RT) in 48% of pts, and avoidance of post-operative RT in 15% of pts (Ladwa et al. 2024). The Neo-SCC trial will evaluate if combined PD-1 plus lymphocyte-activation 3 (LAG3) checkpoint inhibition achieves high path response, while allowing for response-driven surgical and RT de-escalation in pts with resectable cuSCC.

Methods: Pts with histologically confirmed, resectable cuSCC AJCC (8th ed, head/neck) or UICC (9th ed, non-head/neck) clinical stage II, III or IV (M0) are eligible (N = 20). All pts undergo resection (RES) at week 6 following NAT with 2 doses of nivo (480 mg, IV) plus rela (160 mg, IV) at week 0 and 4. LN disease pts undergo baseline index-LN marking and RES at week 6, with subsequent total LN RES if there is no pCR in the index-LN. Synchronous primary/in-transit metastases undergo wide excision during index-LN resection. Non-LN disease pts showing CCR at week 6 receive an incisional biopsy of the baseline tumor site. All non-LN pts undergo definitive excision except those with CCR or pCR on biopsy. RT follows standard care. Imaging includes CT and FDG PET/CT at BL, prior to RES, and during the 5-year follow-up period. Tumor, blood and faecal samples are collected at BL, RES, and recurrence. The primary endpoint is the pCR rate at RES. The sample size is powered to detect a difference > 25% in pCR rate with the historical control. Secondary endpoints include surgical/RT de-scalation rates, RFS, OS, safety/tolerability, surgical outcomes, QOL, and biomarker analyses.

Disclaimer

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Author Details

Maria Gonzalez

Melanoma Institute Australia, Sydney, NSW, Australia

Authors chevron_right

Associated Organizations chevron_right

Abstract Details

Meeting

2025 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

View MoreAbstract Disclosure
open_in_new

Your Privacy

ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.

Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.

For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.

Allow All

Manage Consent Preferences

Essential Website Cookies

Always Active

These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.

They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.

You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.

Cookies Details‎

Performance and Functionality Cookies

Performance and Functionality Cookies

These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.

All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.

Cookies Details‎

Personalization and Analytics Cookies

Personalization and Analytics Cookies

These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.

These cookies may be set by us or by third party providers whose services we have added to our websites.

These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.

Cookies Details‎

Advertising Cookies and Social Media Cookies

Advertising Cookies and Social Media Cookies

Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.

Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.

These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.

If you do not allow these cookies, you may experience less targeted advertising.

Cookies Details‎

Back Button

Cookie List

Search Icon

Filter Icon

Clear

checkbox labellabel

ApplyCancel

ConsentLeg.Interest

checkbox labellabel

checkbox labellabel

checkbox labellabel

• View Cookies

• Name

cookie name

Save Settings

Download

iframeiframeBrand%3B24.0.0.0&uamb=0&uam=&uap=Linux%20x86_64&uapv=6.6.72&uaw=0&fledge=1&data=event%3Dgtag.config)